Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2013

View Archived Issues

Phase III study of GSK-2132231A in melanoma misses first co-primary endpoint

Novartis enters into global licensing and research collaboration with Regenerex

Novartis presents new series of USP2 inhibitors

New mouse model mimics hyperargininemia

Novel TYK2 inhibitors divulged by Takeda Pharmaceuticals

iPierian secures financing to launch spin-out company

Panax ginseng extract prevents adverse cisplatin effects in vivo

New locked nucleic acid antisense oligonucleotides disclosed by U.S. team

Blood smear filipin staining speeds NP-C diagnosis

Lilly presents new mGlu2 positive allosteric modulator for the treatment of anxiety

Novel tricyclic IAP antagonists synthesized at Takeda

FDA accepts corifollitropin alfa NDA for review

Merck KGaA divulges novel protein kinase inhibitors

Oncolytics Biotech reports final tumor response data for phase II study of Reolysin

Bayer Intellectual Property patents new FGFR inhibitors

Neuren Pharmaceuticals cleared to conduct phase II NNZ-2566 trial

Debiopharm and TCG Lifesciences to develop a novel class of antibiotics

Spanish team prepares novel sigma1 receptor ligands

Chimerix begins phase III trial of brincidofovir

BL-8040 receives FDA orphan drug designation for treatment of AML

Gamida Cell reports transplantation of first patient in phase I/II study of NiCord in blood cancers

Aegerion obtains orphan drug designation in Japan for use of lomitapide in treatment of HoFH

Stem Cell Therapeutics to initiate IND-enabling program for CD47 antagonist

FDA grants orphan status to ublituximab for two non-Hodgkin's lymphoma subtypes

Neurocrine discloses results from phase IIb trial of NBI-98854 for treatment of tardive dyskinesia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
CC-3 antibody shows antitumoral activity in penile cancer
BioWorld Science
Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies...